As Light Sciences Oncology waits for clinical trial results, its CEO has moved on to another job. No interim CEO has been named, and the company has not commented on the departure.
Xconomy broke the news after Llew Keltner personally confirmed his departure to Luke Timmerman. The company, which is privately held, does not have to release its Phase III results for its unique cancer therapy, combining drugs and devices to eliminate solid tumors. Light Sciences CFO Bob Littauer told Timmerman that the company has not done the necessary statistical analysis of the trial results yet.
Light Sciences' approach uses a disposable catheter to inject talaporfin sodium directly into a solid tumor. The drug is activated by a light diode, killing the tumor without affecting healthy tissue nearby.